Controlled trial of slowing of Kidney Disease progression From the Inhibition of Xanthine oxidase (CKD-FIX): A double-blind, randomised, placebo-controlled trial

通过抑制黄嘌呤氧化酶 (CKD-FIX) 减缓肾脏疾病进展的对照试验：一项双盲、随机、安慰剂对照试验

• 批准号: nhmrc : 1043203
• 负责人: A/Pr Gopala Rangan
• 金额: $ 134.66万
• 依托单位: The University of Queensland
• 依托单位国家: 澳大利亚
• 项目类别: Project Grants
• 财政年份: 2013
• 资助国家: 澳大利亚
• 起止时间: 2013-01-01 至 2018-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/controlled-trial-slowing-controlled-trial/111558
• 关键词: Controlled; trial; slowing; Kidney; Disease

Chronic kidney disease (CKD) is a major public health problem affecting over 1.5 million Australians and is associated with increased risk of death, heart disease and progression to end-stage kidney disease (ESKD). Current treatments to slow progression to ESKD are limited. The CKD-FIX trial aims to find out whether treatment with allopurinol, a commonly used drug for gout prevention, safely and effectively slows CKD progression. This could lead to significant health and economic benefits.

慢性肾脏疾病（CKD）是影响150多万澳大利亚人的主要公共卫生问题，与死亡、心脏病和进展为终末期肾脏疾病（ESKD）的风险增加有关。目前减缓ESKD进展的治疗是有限的。CKD- fix试验旨在发现别嘌呤醇（一种常用的预防痛风的药物）治疗是否安全有效地减缓CKD进展。这可能带来巨大的健康和经济效益。